Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Thomas A. Zelniker,Marc P. Bonaca,Ofri Mosenzon,Julia F. Kuder,Sabina A. Murphy,Remo Holanda de Mendonça Furtado,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P. H. Wilding,Andrzej Budaj,Róbert Gábor Kiss,Francisco Padilla,Ingrid Gause-Nilsson,Anna Maria Langkilde,Itamar Raz,Marc S. Sabatine,Stephen D. Wiviott

Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

2019

Thomas A. Zelniker
Marc P. Bonaca
Ofri Mosenzon
Julia F. Kuder
Sabina A. Murphy
Remo Holanda de Mendonça Furtado
Deepak L. Bhatt
Lawrence A. Leiter
Darren K. McGuire
John P. H. Wilding
Andrzej Budaj
Róbert Gábor Kiss
Francisco Padilla
Ingrid Gause-Nilsson
Anna Maria Langkilde
Itamar Raz
Marc S. Sabatine
Stephen D. Wiviott

Introduction: Atrial fibrillation (AF) and atrial flutter (AFL) are associated with diabetes and its comorbidities including hypertension, obesity, and heart failure (HF). Sodium-glucose cotranspor...

Keywords:

Internal medicine
Heart failure
Cardiology
Medicine
Diabetes mellitus
Obesity
TIMI
Atrial flutter
Type 2 Diabetes Mellitus
Dapagliflozin
Atrial fibrillation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations